Immunome, Inc. announced plans for a public offering of $400 million of its common stock.
The offering is subject to market conditions and underwritten by Immunome.
The company plans to grant underwriters a 30-day option for additional shares.
Public Offering
Immunome plans to issue and sell $400 million of common stock in a public offering.
Underwriters
Leerink Partners, J.P. Morgan, TD Cowen, Goldman Sachs & Co. LLC, and Guggenheim Securities are serving as joint bookrunning managers.
Registration Statement
The offering is made pursuant to a shelf registration statement on Form S-3 filed with the SEC.
- Immunome is focused on developing targeted cancer therapies.
- The company's pipeline includes promising therapeutics at various stages of development.
- The offering reflects Immunome's commitment to advancing cutting-edge therapies.
The proposed public offering signals Immunome's dedication to advancing cancer treatments and expanding its portfolio.